Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial The following represents disclosure information ...

Background: Adjuvant osimertinib (AO) significantly improved disease-free survival and overall survival among patients with resected stage IB to IIIA epidermal growth factor receptor (EGFR) ...

Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of ...

Among patients with resected stage 3 or 4 melanoma, treatment with immune-oncology agents such as Opdivo (nivolumab) and Yervoy (ipilimumab) demonstrated higher cure rates compared with those treated ...

The combination of a cancer vaccine with Keytruda (pembrolizumab) showed significant improvements in survival without relapse or metastasis versus Keytruda alone in patients with high-risk resected ...

CHICAGO — Adjuvant osimertinib conferred a significant OS benefit vs. placebo among patients with resected, EGFR-mutant, stage IB to IIIA non-small cell lung cancer, according to results of the ...

CHICAGO — Adjuvant pembrolizumab significantly improved distant metastasis-free survival among patients with resected stage IIB or IIC melanoma, according to results of the phase 3 KEYNOTE-716 ...

TG4050, a personalized neoantigen vaccine, induced tumor-specific immune responses and led to low rates of disease relapse in patients with surgically resected HPV-negative head and neck squamous ...

The Company is awaiting feedback by mid-June 2025 from a Type D meeting with FDA regarding the statistical analysis plan to be used in an End of Phase 2 meeting for OST-HER2 in the prevention of ...